Announcements Trials
Browse Landscape

Phase

Phase 2/3 2Phase NA 1

Status

Recruiting 2Completed 1

Sponsor Class

OTHER 2FED 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Prostatic Neoplasms 30Neoplasm Metastasis 3Metastatic Hormone-sensitive Prostate Cancer (mHSPC) 2Metastatic Castration-resistant Prostate Cancer 2Urologic Diseases 1Urogenital Neoplasms 1Triple Negative Breast Neoplasms 1Radiation Injuries 1Prostatic Diseases 1Prostate Cancer Metastatic 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Oligometastatic Prostate Cancer 1Neoplasm Recurrence, Local 1Metastatic Hormone Sensitive Prostate Cancer 1Metastatic Castrate-sensitive Prostate Cancer 1Hormone Sensitive Prostate Cancer 1Genital Neoplasms, Male 1Gastrointestinal Diseases 1Breast Neoplasms 1Adenocarcinoma 1

Interventions

Specimen Handling 43pembrolizumab 42Biopsy 36Magnetic Resonance Spectroscopy 34Paclitaxel 21Carboplatin 21Gemcitabine 20Nivolumab 19Irinotecan 17Radiosurgery 15Cisplatin 13Taxes 11Pemetrexed 11Ipilimumab 11Fluorouracil 11Cetuximab 11trastuzumab deruxtecan 10olaparib 10Leucovorin 10130-nm albumin-bound paclitaxel 10abemaciclib 9Oxaliplatin 9Cyclophosphamide 9Capecitabine 9Bevacizumab 9palbociclib 8durvalumab 8Fulvestrant 8X-Rays 7Trastuzumab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Neoplasm Metastasis × Androgen Antagonists × 90 days × Clear all
NCT03644303 2026-05-14

TRAP

Royal Marsden NHS Foundation Trust

Phase NA Completed
86 enrolled 27 charts
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT04787744 2026-04-08

VA STARPORT

VA Office of Research and Development

Phase 2/3 Recruiting
464 enrolled
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT07426094 2026-03-23

PRO-BOOST-N

Affidea Nu-med Center of Oncological DIagnostics and Therapy

Phase 2/3 Recruiting
1,600 enrolled
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡